… receiving ECMO (23). The aims of this paper were to describe the population PK of
piperacillin and tazobactam in critically ill adults receiving ECMO with and without RRT and to …

… commonly prescribed to critically ill patients placed on … pharmacokinetic data in critically ill
patients undergoing CKRT to better understand pharmacokinetics of pip-tazo in this population…

… The aim of this study was to assess the PK of piperacillin in critically ill patients treated
with CI. A population PK model was developed to identify patient covariates and evaluate the …

… therapy (CRRT), may alter the pharmacokinetics of piperacillin-tazobactam. We aimed to …
a population pharmacokinetic model of piperacillin-tazobactam in critically ill patients during …

… of both piperacillin and tazobactam in critically ill patients. … population PK model of
piperacillin/tazobactam that is suitable for critically ill Korean adult patients, including those receiving …

… was to characterize tazobactam PK in a cohort of critically ill patients with Gram… population
PK modeling approach. Currently, a population model that characterizes the pharmacokinetics …

… piperacillin-tazobactam and provides comprehensive data on current dosing strategies while
identifying significant covariates in critically ill patients… care unit OR critically ill). Additionally…

… Six models were evaluated with a dataset consisting of 30 critically ill patients (35 samples)
receiving piperacillin by continuous infusion. Models were subject to prediction-based (bias …

… PIP concentrations between 200 and 300 mg/L up to 60 h after treatment initiation have
been documented in a prospective study conducted among 18 critically ill patients treated with …

… adults, a dedicated PK study for piperacillin/tazobactam is indicated to optimize dosing. …
a population PK modeling approach to quantify how the systemic CL of piperacillin/tazobactam …